Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IPL344 Continued Treatment in ALS
NCT03755167Phase 2Suspended
- Sponsor
- Immunity Pharma
- Start
- Dec 2018
- Primary completion
- Jan 2027
- Modality
- Peptides, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of IPL344 in amyotrophic lateral sclerosis (ALS), sponsored by Immunity Pharma. Started Dec 2018; status: suspended.
02
Drugs
IPL344
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT03755167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03755167.